

NOV 2 1 2007

Food and Drug Administration Rockville MD 20857

Re: Lucentis Patent Nos. 6,407,213 6,884,879 Docket Nos. 2007E-0424

2007E-0425

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent Nos. 6,407,213 and 6,884,879 filed by Genentech, Inc. under 35 U.S.C. § 156. The human biological product claimed by these patents is Lucentis (ranibizumab), which was assigned biologic license application (BLA) No. 125156/0.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in *Glaxo Operations UK Ltd. v. Quigg*, 706 F. Supp. 1224 (E.D. Va. 1989), aff'd, 894 F. 2d 392 (Fed. Cir. 1990).

The BLA was approved on June 30, 2006, which makes the submission of the patent term extension applications on August 25, 2006, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patents are eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane a. afulla.

Associate Director for Policy

Center for Drug Evaluation and Research

Dudas – Lucentis Patent Nos. 6,407,213 and 6,884,879 Page 2

cc:

Jeffrey P. Kushan SIDLEY AUSTIN LLP 1501 K Street, N.W. Washington, DC 20005